Journal
ANNUAL REVIEW OF MEDICINE, VOL 69
Volume 69, Issue -, Pages 409-419Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-061016-041032
Keywords
HIV-1; broadly neutralizing antibodies (bNAbs); immunotherapy
Categories
Ask authors/readers for more resources
Broadly neutralizing antibodies (bNAbs) have been evaluated as promising agents in the fight against infectious diseases. HIV-1-specific bNAbs, in particular, have been tested in both preventive and therapeutic modalities. Multiple bNAbs have been isolated, characterized, and assessed in vitro and in vivo, but no single antibody appears to possess the breadth and potency that may be needed if it is to be used in the treatment of HIV-1 infection. With the technological advances of the past decades, novel and more effective bNAbs have been identified or engineered for higher neutralizing potency, greater breadth, and increased serum half-life. In this review, we discuss the development of a new generation of anti-HIV-1 bNAbs and their potential to be used clinically for treatment and prevention of HIV-1 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available